{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:55:16Z","timestamp":1768971316369,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2017YFC1309004"],"award-info":[{"award-number":["2017YFC1309004"]}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine","award":["2017-I2M-1-005"],"award-info":[{"award-number":["2017-I2M-1-005"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2019-I2M-2-002"],"award-info":[{"award-number":["2019-I2M-2-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00432-020-03166-1","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T18:23:58Z","timestamp":1583259838000},"page":"1307-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm"],"prefix":"10.1007","volume":"146","author":[{"given":"Yuanyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-753X","authenticated-orcid":false,"given":"Xuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"3166_CR1","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.31275","volume":"142","author":"P Christopoulos","year":"2018","unstructured":"Christopoulos P, Endris V, Bozorgmehr F et al (2018) EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. Int J Cancer 142:2589\u20132598. https:\/\/doi.org\/10.1002\/ijc.31275","journal-title":"Int J Cancer"},{"key":"3166_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/JTO.0b013e318274a83e","volume":"8","author":"CM Conklin","year":"2013","unstructured":"Conklin CM, Craddock KJ, Have C et al (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8:45\u201351. https:\/\/doi.org\/10.1097\/JTO.0b013e318274a83e","journal-title":"J Thorac Oncol"},{"key":"3166_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1309\/AJCPUQB18XZOHHBJ","volume":"134","author":"EE Grimm","year":"2010","unstructured":"Grimm EE, Schmidt RA, Swanson PE et al (2010) Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol 134:284\u2013292. https:\/\/doi.org\/10.1309\/AJCPUQB18XZOHHBJ","journal-title":"Am J Clin Pathol"},{"key":"3166_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.tranon.2019.02.015","volume":"12","author":"A Guyard","year":"2019","unstructured":"Guyard A, Charpy C, Th\u00e9ou-Anton N et al (2019) Isolated 5' signals are an atypical pattern to be considered as positive for ALK rearrangement: a brief report of three cases and review of the literature. Transl Oncol 12:784\u2013787. https:\/\/doi.org\/10.1016\/j.tranon.2019.02.015","journal-title":"Transl Oncol"},{"key":"3166_CR5","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/j.jtho.2016.11.2229","volume":"12","author":"JM Heuckmann","year":"2017","unstructured":"Heuckmann JM, Pauwels P, Thunnissen E et al (2017) Comprehensive hybrid capture-based next-generation sequencing identifies a double ALK gene fusion in a patient previously identified to be false-negative by FISH. J Thorac Oncol 12:e22\u2013e24. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2229","journal-title":"J Thorac Oncol"},{"key":"3166_CR6","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","volume":"21","author":"R Katayama","year":"2015","unstructured":"Katayama R, Lovly CM, Shaw AT (2015) Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21:2227\u20132235. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2791","journal-title":"Clin Cancer Res"},{"key":"3166_CR7","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/onc.2016.486","volume":"36","author":"HS Kim","year":"2017","unstructured":"Kim HS, Jung M, Kang HN et al (2017) Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition. Oncogene 36:3334\u20133345. https:\/\/doi.org\/10.1038\/onc.2016.486","journal-title":"Oncogene"},{"key":"3166_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/JTO.0000000000000030","volume":"9","author":"T Li","year":"2014","unstructured":"Li T, Maus MK, Desai SJ et al (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18\u201325. https:\/\/doi.org\/10.1097\/JTO.0000000000000030","journal-title":"J Thorac Oncol"},{"key":"3166_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2016.08.145","volume":"12","author":"W Li","year":"2017","unstructured":"Li W, Zhang J, Guo L et al (2017) Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 12:94\u2013101. https:\/\/doi.org\/10.1016\/j.jtho.2016.08.145","journal-title":"J Thorac Oncol"},{"key":"3166_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 13:323\u2013358. https:\/\/doi.org\/10.1016\/j.jtho.2017.12.001","journal-title":"J Thorac Oncol"},{"key":"3166_CR11","doi-asserted-by":"publisher","DOI":"10.3791\/56342","author":"X Lv","year":"2017","unstructured":"Lv X, Zhao M, Yi Y et al (2017) Detection of rare mutations in ctDNA using next generation sequencing. J Vis Exp. https:\/\/doi.org\/10.3791\/56342","journal-title":"J Vis Exp"},{"key":"3166_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2017.12.004","volume":"116","author":"A McLeer-Florin","year":"2018","unstructured":"McLeer-Florin A, Duruisseaux M, Pinsolle J et al (2018) ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer 116:15\u201324. https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.004","journal-title":"Lung Cancer"},{"key":"3166_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2013.01.004","volume":"15","author":"EC Minca","year":"2013","unstructured":"Minca EC, Portier BP, Wang Z et al (2013) ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 15:341\u2013346. https:\/\/doi.org\/10.1016\/j.jmoldx.2013.01.004","journal-title":"J Mol Diagn"},{"key":"3166_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/his.13198","volume":"71","author":"N Nakajima","year":"2017","unstructured":"Nakajima N, Yoshizawa A, Kondo K et al (2017) Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement. Histopathology 71:143\u2013149. https:\/\/doi.org\/10.1111\/his.13198","journal-title":"Histopathology"},{"key":"3166_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11864-017-0513-x","volume":"18","author":"X Niu","year":"2017","unstructured":"Niu X, Chuang JC, Berry GJ et al (2017) Anaplastic lymphoma kinase testing: IHC vs. FISH vs. NGS. Curr Treat Options Oncol 18:71. https:\/\/doi.org\/10.1007\/s11864-017-0513-x","journal-title":"Curr Treat Options Oncol"},{"key":"3166_CR16","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1097\/JTO.0b013e3182614ab5","volume":"7","author":"N Peled","year":"2012","unstructured":"Peled N, Palmer G, Hirsch FR et al (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7:e14\u201316. https:\/\/doi.org\/10.1097\/JTO.0b013e3182614ab5","journal-title":"J Thorac Oncol"},{"key":"3166_CR17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jtho.2017.07.026","volume":"12","author":"B Poirot","year":"2017","unstructured":"Poirot B, Doucet L, Benhenda S et al (2017) MET Exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels. J Thorac Oncol 12:1582\u20131587. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.026","journal-title":"J Thorac Oncol"},{"key":"3166_CR18","doi-asserted-by":"publisher","first-page":"e14826","DOI":"10.1097\/MD.0000000000014826","volume":"98","author":"Y Qiu","year":"2019","unstructured":"Qiu Y, Li B, Zhang Y et al (2019) ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: a case report. Medicine (Baltimore) 98:e14826. https:\/\/doi.org\/10.1097\/MD.0000000000014826","journal-title":"Medicine (Baltimore)"},{"key":"3166_CR19","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/JTO.0000000000000013","volume":"9","author":"S Ren","year":"2014","unstructured":"Ren S, Hirsch FR, Varella-Garcia M et al (2014) Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 9:e21\u201323. https:\/\/doi.org\/10.1097\/JTO.0000000000000013","journal-title":"J Thorac Oncol"},{"key":"3166_CR20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","volume":"46","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Rodig SJ, Chirieac LR et al (2010) The biology and treatment of EML4\u2013ALK non-small cell lung cancer. Eur J Cancer 46:1773\u20131780. https:\/\/doi.org\/10.1016\/j.ejca.2010.04.002","journal-title":"Eur J Cancer"},{"key":"3166_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/his.12708","volume":"67","author":"C Selinger","year":"2015","unstructured":"Selinger C, Cooper W, Lum T et al (2015) Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. Histopathology 67:654\u2013663. https:\/\/doi.org\/10.1111\/his.12708","journal-title":"Histopathology"},{"key":"3166_CR22","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247\u20134253. https:\/\/doi.org\/10.1200\/JCO.2009.22.6993","journal-title":"J Clin Oncol"},{"key":"3166_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566","journal-title":"Nature"},{"key":"3166_CR24","doi-asserted-by":"publisher","first-page":"19893","DOI":"10.1073\/pnas.0805381105","volume":"105","author":"M Soda","year":"2008","unstructured":"Soda M, Takada S, Takeuchi K et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 105:19893\u201319897. https:\/\/doi.org\/10.1073\/pnas.0805381105","journal-title":"Proc Natl Acad Sci USA"},{"key":"3166_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CCO.0000000000000431","volume":"30","author":"AA Thai","year":"2018","unstructured":"Thai AA, Solomon BJ (2018) Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol 30:84\u201391. https:\/\/doi.org\/10.1097\/CCO.0000000000000431","journal-title":"Curr Opin Oncol"},{"key":"3166_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","volume":"114","author":"HX Tian","year":"2017","unstructured":"Tian HX, Zhang XC, Yang JJ et al (2017) Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer 114:90\u201395. https:\/\/doi.org\/10.1016\/j.lungcan.2017.11.001","journal-title":"Lung Cancer"},{"key":"3166_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-018-0735-1","volume":"37","author":"Y Tong","year":"2018","unstructured":"Tong Y, Zho Z, Liu B et al (2018) 5'\/ 3\u2032 imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer. J Exp Clin Cancer Res 37:68. https:\/\/doi.org\/10.1186\/s13046-018-0735-1","journal-title":"J Exp Clin Cancer Res"},{"key":"3166_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/gcc.22047","volume":"52","author":"K Tuononen","year":"2013","unstructured":"Tuononen K, M\u00e4ki-Nevala S, Sarhadi VK et al (2013) Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 52:503\u2013511. https:\/\/doi.org\/10.1002\/gcc.22047","journal-title":"Genes Chromosomes Cancer"},{"key":"3166_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2016.01.014","volume":"94","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu Y, Zhao C et al (2016) Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR. Lung Cancer 94:28\u201334. https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.014","journal-title":"Lung Cancer"},{"key":"3166_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41379-019-0212-1","volume":"32","author":"J Wang","year":"2019","unstructured":"Wang J, Yi Y, Xiao Y et al (2019) Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 32:1053\u20131064. https:\/\/doi.org\/10.1038\/s41379-019-0212-1","journal-title":"Mod Pathol"},{"key":"3166_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"3166_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","volume":"9","author":"MW Wynes","year":"2014","unstructured":"Wynes MW, Sholl LM, Dietel M et al (2014) An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 9:631\u2013638. https:\/\/doi.org\/10.1097\/JTO.0000000000000115","journal-title":"J Thorac Oncol"},{"key":"3166_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3760\/cma.j.issn.0529-5807.2018.04.003","volume":"47","author":"XC Zhang","year":"2018","unstructured":"Zhang XC, Lu S, Zhang L et al (2018) Guideline for diagnosis and treatment of ALK and ROS1 positive non-small cell lung cancer in China. Zhonghua Bing Li Xue Za Zhi 47:241\u2013247. https:\/\/doi.org\/10.3760\/cma.j.issn.0529-5807.2018.04.003","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"3166_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2016.01.011","volume":"94","author":"W Zhao","year":"2016","unstructured":"Zhao W, Choi YL, Song JY et al (2016) ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 94:22\u201327. https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.011","journal-title":"Lung Cancer"},{"key":"3166_CR35","doi-asserted-by":"publisher","first-page":"120200","DOI":"10.1016\/j.talanta.2019.120200","volume":"206","author":"X Zhu","year":"2020","unstructured":"Zhu X, Liu B, Su S et al (2020) A \"quasi\" confocal droplet reader based on laser-induced fluorescence (LIF) cytometry for highly-sensitive and contamination-free detection. Talanta 206:120200. https:\/\/doi.org\/10.1016\/j.talanta.2019.120200","journal-title":"Talanta"},{"key":"3166_CR36","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1039\/c9an00637k","volume":"144","author":"X Zhu","year":"2019","unstructured":"Zhu X, Su S, Fu M et al (2019) A density-watershed algorithm (DWA) method for robust, accurate and automatic classification of dual-fluorescence and four-cluster droplet digital PCR data. Analyst 144:4757\u20134771. https:\/\/doi.org\/10.1039\/c9an00637k","journal-title":"Analyst"},{"key":"3166_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1586\/14737140.2016.1162098","volume":"16","author":"F Zito Marino","year":"2016","unstructured":"Zito Marino F, Rocco G, Morabito A et al (2016) A new look at the ALK gene in cancer: copy number gain and amplification. Expert Rev Anticancer Ther 16:493\u2013502. https:\/\/doi.org\/10.1586\/14737140.2016.1162098","journal-title":"Expert Rev Anticancer Ther"},{"key":"3166_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/cncy.21835","volume":"125","author":"F Zito Marino","year":"2017","unstructured":"Zito Marino F, Rossi G, Brunelli M et al (2017) Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: cytological smears versus cell blocks. Cancer Cytopathol 125:303\u2013312. https:\/\/doi.org\/10.1002\/cncy.21835","journal-title":"Cancer Cytopathol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03166-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:39:54Z","timestamp":1614731994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03166-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["3166"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03166-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"25 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The retrospective study was approved by the institutional review board of Peking Union Medical College Hospital with a waiver for the need to obtain informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}